We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting

By LabMedica International staff writers
Posted on 02 Aug 2016
Image: The cobas c 513 high-throughput HbA1c analyzer (Photo courtesy of Roche).
Image: The cobas c 513 high-throughput HbA1c analyzer (Photo courtesy of Roche).
A fully automated, high-throughput system for HbA1c testing will be available for inspection at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Roche (Basel, Switzerland) will introduce the cobas c 513 analyzer at Booth 1301 of the Philadelphia expo. The c 513 is a fully automated, high-throughput HbA1c testing solution with a module that can reach a throughput of up to 400 determinations per hour. The reagent compartment has 60 reagent positions that can be loaded providing up to 14,000 results.

The instrument features direct results reporting, which minimizes the risk of result misinterpretation and eliminates the need for performing time-consuming, manual result interpretation. This new analyzer also offers closed tube sampling, which reduces hands-on time, prevents sample contamination, and ensures operator safety.

As the instrument is still awaiting FDA 510(k) approval, the c 513 is not currently available in the USA.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Roche
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more